[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"terminal-illness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:terminal-illness":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,93,124,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100642173","empowering-monterey-bay-residents-for-activated-collaborative-and-equitable-care-100642173",false,"NCT07652359","Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care","EMBRACE - Empowering Monterey Bay Residents for Activated, Collaborative, and Equitable Care","EMBRACE","Inclusion Criteria:\n\n* Participants must be receiving clinical care by a primary care physician in the Monterey area\n* Participants must be 18 years or older.\n* Participants must speak either English or Spanish.\n* Participants must be able to consent verbally in English or Spanish to all study procedures.\n* Participants must self-identify as a racial\u002Fethnic minorities OR identify as having low-income status\n\nExclusion Criteria:\n\n\\- Patients unable to respond to survey questions in either English or Spanish.","ALL","18 Years",{"count":20,"type":21},138,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of the EMBRACE Study is to evaluate whether a facilitated intervention improves shared decision-making (SDM) and patient activation among low-income and minority individuals more than usual care only. The ultimate goal is to enhance SDM and patient activation in care.",[27,28,29,30],"Shared Decision-Making","Quality of Life","Advanced Illness","Terminal Illness",[32,33],"Goals of care","Advanced care planning","NOT_YET_RECRUITING","2026-06-10",{"date":37,"type":38},"2026-06-17","ACTUAL",{"date":40,"type":21},"2026-10-01",{"date":42,"type":21},"2030-01-01",{"name":44,"class":45},"Stanford University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":72,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":4},"100629619","non-invasive-detection-and-preservation-of-neurocognitive-signals-in-the-peri-death-period-using-brain-computer-interface-and-artificial-intelligence-100629619","NCT07477028","Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence","Feasibility of Non-Invasive Detection and Preservation of Neurocognitive Signals in the Peri-Death Period Using Brain-Computer Interface and Artificial Intelligence: A Prospective Observational Study (NeuroCogPresv)","NeuroCogPresv","Inclusion Criteria:\n\n1. Adults ≥18 years with terminal illness or severe acute trauma\n2. Do-not-resuscitate (DNR\u002FDNI) order in place\n3. Surrogate decision-maker available and willing to provide informed consent\n4. Expected survival ≤7 days (physician estimate)\n\nExclusion Criteria:\n\n1. Brain death already declared \\> 24 hours prior to enrollment\n2. Contraindication to EEG\u002FBCI headset placement (e.g., severe scalp injury)\n3. Patient lacks a legally authorized representative",{"count":55,"type":21},20,"OBSERVATIONAL","Background: Recent electroencephalography (EEG) data indicate that the transition from clinical death to cellular death is marked by highly organized neurophysiological events, including significant surges in gamma-band power, cross-frequency coupling, and distinct spreading depolarization waves. This prospective, observational feasibility study utilizes rapid-deployment, high-density, noninvasive BCI hardware paired with proprietary AI analytics to detect, classify, and securely archive these terminal neurocognitive signals.\n\nObjectives: (1) Quantify transient gamma-band activity and cross-frequency connectivity post-clinical death; (2) Validate the efficacy of machine learning models for real-time signal classification in high-noise clinical environments; (3) Establish a highly secure, encrypted bio-informational archive of peri-life EEG data.\n\nDesign: Prospective, open-label, multicenter, observational cohort (n\\>20).",[30,59,60,61,62,63,64,65,66,67,68,69,70,71],"End-of-Life Care","Death","Brain Death","Death Anxiety","Consciousness","Electroencephalography","Gamma Oscillations","Near-Death Phenomena","Cognitive","Cognition","Memory","EEG","Severe Acute Trauma",[73,74,75,60,65,68,63,76,77,78,69,79,80,81,82],"AI","BCI","Brain Computer Interface","Pefi-death","Brain death","Reservation","Life","Life experience","Transfer","Convergence","2026-03-12",{"date":85,"type":38},"2026-03-17",{"date":87,"type":21},"2026-09-01",{"date":89,"type":21},"2035-09-30",{"name":91,"class":92},"Noah Tech, Corp.","INDUSTRY",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":22,"phases":102,"briefSummary":103,"conditions":104,"keywords":106,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":123},"100563375","digipall-a-trial-of-digital-patient-reported-outcome-and-biomarker-monitoring-in-palliative-care-100563375","NCT06615349","DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care","DigiPall; a Randomized Controlled Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care","Inclusion Criteria:\n\n* Patients with established diagnosis of a metastatic cancer\u002Fsevere illness with limited life expectancy receiving palliative care services\n* Estimated life expectancy \\\u003C24 months (physician's guess)\u002F \\>3 months\n* Karnofsky Index ≥ 50% \u002F ECOG≤ 2\n* Aged \\>18 years\n* Owns and uses a smartphone\n* Give written informed consent\n\nExclusion Criteria:\n\n* Patients under curative treatment\n* Relevant cognitive impairment",{"count":101,"type":21},382,[24],"The aim of this study is to test if a system consisting of a wearable device measuring heartbeats and steps, together with daily communication with a chatbot on the smartphone asking the patients about their symptoms and giving tips, can reduce unplanned hospital readmissions and improve well-being in advanced cancer and severely ill patients.",[30,105],"Terminal Cancer",[107,108,109,110,111,112],"Palliative Care","chatbot","wearable","PROMs","rehospitalisation","mobile health","RECRUITING","2025-07-07",{"date":116,"type":38},"2025-07-10",{"date":118,"type":38},"2025-06-11",{"date":120,"type":21},"2027-09",{"name":122,"class":45},"David Blum",1,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":123},"100524411","differences-in-acceptability-of-music-therapy-sessions-played-live-compared-to-a-recording-thereof-100524411","NCT06108375","Differences in Acceptability of Music Therapy Sessions Played Live Compared to a Recording Thereof","Inclusion Criteria:\n\n* Age \\>18 years old\n* Capacity to provide informed consent\n* Patients with established diagnosis of a metastatic cancer\u002Fsevere illness with limited life expectancy on a palliative care ward at the University Hospital Zurich\n\nExclusion Criteria:\n\n• Inability to answer a questionnaire due to physical limitations as well as cognitive or linguistic reasons.",{"count":131,"type":21},25,[24],"The present study seeks to assess differences in feasibility and acceptability of music therapy played live and listening to a recording thereof at the palliative care ward of the University Hospital Zurich. As a secondary objective the investigators aim to extend the limited findings on the putative effect of music therapy in palliative care populations derived from objective measures of human autonomic response combined with subjective psychological outcomes to support evidence-based medicine. The investigators will implement a commercially available tracker, the wristband 287-2 by Corsano, to investigate multiple simultaneous biomarkers of autonomic response to music therapy and a recording thereof, such as heart rate, heart rate variability, electrodermal activity and distal body temperature.\n\nTo investigate subjective quality of life and psychological outcomes, the investigators will administer highly validated and widely used questionnaires, namely the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 15 Palliative Care, the Edmonton Symptom Assessment System and the Hospital Anxiety and Depression Scale.",[30,105],{"date":136,"type":38},"2025-07-11",{"date":138,"type":38},"2023-10-24",{"date":140,"type":21},"2026-03",{"name":142,"class":45},"University of Zurich",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":150,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":123},"100382253","transcranial-magnetic-stimulation-for-psychological-distress-in-patients-with-advanced-illness-100382253","NCT04257227","Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness","Transcranial Magnetic Stimulation for Psychological Distress in Patients With Advanced Illness: A Phase 2a\u002F2b Dose-finding and Feasibility Clinical Trial","Inclusion Criteria:\n\n* PC unit patients and PC patients in the community with advanced (terminal) illness\n* \\>1 month life expectancy\n* Experiencing psychological distress, as indicated by a score of 7 or greater on the Depression, Anxiety, or Well-being subscale of the Edmonton Symptom Assessment System (ESAS)\n* Ability to understand and communicate in English\n\nExclusion Criteria:\n\n* Current or previously diagnosed seizure disorder or first-degree relative with current or previously diagnosed seizure disorder\n* Documented brain lesions\n* Inability to remain still while sitting up (45 degrees) for the duration of therapy\n* Known contraindications to rTMS, including: metallic skull plates, clips, or stimulators; pacemakers and other electronic implants; pregnancy; recurrent headaches with no known cause that do not respond to over-the-counter medications; current or previous skull fracture or traumatic brain injury; previous brain surgery; medications that lower seizure threshold",{"count":151,"type":21},15,[24],"Psychological and existential distress are a common cause of suffering among patients nearing the end of life, and a major reason for requesting medical aid in dying. Existing treatments for psychological and existential suffering have low efficacy and are challenging to use in a palliative context. There is a need to develop scalable, brief, and rapidly effective therapeutic approaches that can reduce psychological and existential distress in patients nearing the end of life.\n\nRepetitive Transcranial Magnetic Stimulation is an effective treatment for refractory depression, and new protocols and increasing availability of rTMS may make this therapy feasible and acceptable for patients who suffer from psychological or existential distress near the end of life.\n\nAmong patients with advanced illness followed by a PC provider, the study objectives are to:\n\n1. Identify the lowest and range of therapeutic rTMS dose to relieve psychological distress, including an analysis of clinical predictors of response.\n2. Test the feasibility and preliminary efficacy of rTMS for the treatment of psychological distress including: 1) ease of recruitment; 2) completion of follow-up; 3) effect size and variance estimates of treatment for primary and secondary outcomes; and 4) patient satisfaction with treatment.\n\nThis study is a phase 2a dose-finding open-label clinical trial, followed by a phase 2b prospective, sham-control or sham-crossover study, depending on the therapeutic dose identified in phase 2a.\n\nThe investigators will enroll eligible patients from an inpatient palliative care unit and administer rTMS according to established best practice international guidelines. Two screening tests will be conducted (one completed by patient and another by the treating physician) to ensure the patient has no contraindications to rTMS. In the open-label dose-finding study, investigators will determine the appropriate dose of treatment that leads to positive patient outcomes, assess characteristics associated with positive and rapid response to rTMS, and examine if this treatment is feasible and acceptable to patients by measuring rates of enrollment and completion of the treatment sessions. Based on results from this first phase, a phase 2b feasibility and preliminary efficacy randomized clinical trial will be conducted to measure the effect of rTMS by comparing patient symptoms before and after the rTMS intervention.",[155,156,157,30],"Depressive Symptoms","Depression, Anxiety","Psychological Distress",[159,160,161,162,163],"palliative care","end of life","repetitive transcranial magnetic stimulation","dose-finding","feasibility","2024-08-07",{"date":166,"type":38},"2024-08-09",{"date":168,"type":38},"2020-11-02",{"date":170,"type":21},"2025-01-20",{"name":172,"class":45},"Ottawa Hospital Research Institute"]